Tang Capital Management LLC
About Tang Capital Management LLC’s 13F portfolio
Tang Capital Management LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Tang Capital Management LLC reported $2.2B across 41 US-listed positions (). Its largest position is AURINIA PHARMACEUTICALS INC (AUPH) at 10% of the reported book, and its ten biggest holdings make up 63% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: AUPH AURINIA PHARMACEUTICALS INC | — — | 10% | 13.0M | $221.4M |
| 2 | NASDAQ: SYRE SPYRE THERAPEUTICS INC | — — | 7.6% | 1.9M | $168.0M |
| 3 | NASDAQ: MIRM MIRUM PHARMACEUTICALS INC | — — | 6.6% | 1.2M | $144.7M |
| 4 | NASDAQ: KNSA KINIKSA PHARMACEUTICALS INTL | — — | 6.6% | 2.3M | $144.5M |
| 5 | NASDAQ: CELC CELCUITY INC | — — | 6.2% | 1.3M | $137.5M |
| 6 | NASDAQ: CORT CORCEPT THERAPEUTICS INC | — — | 5.9% | 1.5M | $130.4M |
| 7 | NASDAQ: PTCT PTC THERAPEUTICS INC | — — | 5.6% | 1.5M | $122.4M |
| 8 | NASDAQ: GLPG LAKEFRONT BIOTHERAPEUTICS NV | — — | 5.2% | 3.8M | $113.5M |
| 9 | NASDAQ: CAPR CAPRICOR THERAPEUTICS INC | — — | 4.5% | 4.1M | $98.7M |
| 10 | NASDAQ: TARS TARSUS PHARMACEUTICALS INC | — — | 4.5% | 1.6M | $98.7M |
| 11 | NYSE Arca: SPY STATE STR SPDR S&P 500 ETF T | — — | 4.2% | 123K | $91.9M |
| 12 | NASDAQ: ANAB ANAPTYSBIO INC | — — | 4.1% | 1.3M | $89.8M |
| 13 | NASDAQ: IMCR IMMUNOCORE HLDGS PLC | — — | 3.8% | 2.6M | $84.1M |
| 14 | NASDAQ: CMPS COMPASS PATHWAYS PLC | — — | 3.2% | 5.0M | $70.8M |
| 15 | NASDAQ: ANIP ANI PHARMACEUTICALS INC | — — | 2.7% | 708K | $58.6M |
| 16 | NASDAQ: BNTX BIONTECH SE | — — | 2.0% | 470K | $43.7M |
| 17 | NASDAQ: CMPX COMPASS THERAPEUTICS INC | — — | 1.8% | 18.0M | $39.4M |
| 18 | NASDAQ: PGEN PRECIGEN INC | — — | 1.7% | 6.4M | $36.6M |
| 19 | NASDAQ: VRDN VIRIDIAN THERAPEUTICS INC | — — | 1.5% | 1.8M | $32.9M |
| 20 | NASDAQ: NVCT NUVECTIS PHARMA INC | — — | 1.3% | 1.6M | $28.5M |
| 21 | NASDAQ: DNTH DIANTHUS THERAPEUTICS INC | — — | 1.2% | 265K | $25.8M |
| 22 | NASDAQ: FULC FULCRUM THERAPEUTICS INC | — — | 1.1% | 6.5M | $23.9M |
| 23 | NASDAQ: AVIR ATEA PHARMACEUTICALS INC | — — | 1.0% | 4.8M | $22.4M |
| 24 | NASDAQ: CBIO CRESCENT BIOPHARMA INC. | — — | 0.9% | 1.2M | $20.9M |
| 25 | NASDAQ: NNDM NANO DIMENSION LTD | — — | 0.9% | 14.3M | $20.7M |
Showing 1–25 of 41 positions on this page reported in this 13F.
- Healthcare95%
- Technology0.9%
- AddedAUPHAURINIA PHARMACEUTICALS INC+6.7%$221.4M
- AddedCELCCELCUITY INC+25.2%$137.5M
- AddedCAPRCAPRICOR THERAPEUTICS INC+20.6%$98.7M
- AddedTARSTARSUS PHARMACEUTICALS INC+31.9%$98.7M
- AddedCMPSCOMPASS PATHWAYS PLC+24.9%$70.8M
- AddedCMPXCOMPASS THERAPEUTICS INC+7.1%$39.4M
- NewNVCTNUVECTIS PHARMA INC—$28.5M
- NewFULCFULCRUM THERAPEUTICS INC—$23.9M
- NewNNDMNANO DIMENSION LTD—$20.7M
- AddedNUVBNUVATION BIO INC+4.8%$18.7M
- ReducedSPYSTATE STR SPDR S&P 500 ETF T−26.8%$91.9M
- ReducedINSMINSMED INC−61.5%$10.7M
- ReducedSTOKSTOKE THERAPEUTICS INC−40.0%$9.8M
- ReducedPLRXPLIANT THERAPEUTICS INC−0.0%$7.0M
- ReducedMRNAMODERNA INC−50.0%$3.5M
- SoldNMRANEUMORA THERAPEUTICS INC.−100%—
- SoldJANXJANUX THERAPEUTICS INC−100%—
- SoldKALVKALVISTA PHARMACEUTICALS INC−100%—
- SoldABEOABEONA THERAPEUTICS INC−100%—
- SoldEOLSEVOLUS INC−100%—
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | — ITeos Therapeutics, Inc. | 13D | 100.0%! | 10K | Filed 03 SEP 2025 |
| 2 | — Cargo Therapeutics, Inc. | 13D | 100.0%! | 10K | Filed 21 AUG 2025 |
| 3 | — Allakos Inc. | 13D | 100.0%! | 10K | Filed 19 MAY 2025 |
| 4 | BOLD Boundless Bio, Inc. | 13G | 12.5% | 2.8M | Filed 16 NOV 2026 |
| 5 | FULC Fulcrum Therapeutics, Inc. | 13G | 10.4% | 6.9M | Filed 15 JUL 2026 |
| 6 | CMPX Compass Therapeutics, Inc. | 13G | 10.0% | 17.2M | Filed 14 NOV 2025 |
| 7 | PMVP PMV Pharmaceuticals, Inc. | 13G | 10.0% · 2 classes | 7.6M | Filed 16 NOV 2026 |
| 8 | KALV KalVista Pharmaceuticals, Inc. | 13G | 9.9% | 4.9M | Filed 15 MAY 2025 |
| 9 | EYPT EyePoint, Inc. | 13G | 9.6% | 8.3M | Filed 27 OCT 2026 |
| 10 | PLRX Pliant Therapeutics, Inc. | 13D | 9.6% | 5.9M | Filed 10 MAR 2025 |
| 11 | AUPH Aurinia Pharmaceuticals Inc. | 13D | 9.2% · 2 classes | 12.2M | Filed 03 MAR 2026 |
| 12 | NNDM Nano Dimension Ltd. | 13G | 9.1% | 19.2M | Filed 21 AUG 2026 |
| 13 | GLPG Galapagos NV | 13G | 8.4% | 5.6M | Filed 29 OCT 2025 |
| 14 | DERM Journey Medical Corporation | 13G | 8.0% | 1.9M | Filed 15 MAY 2025 |
| 15 | PRTC PureTech Health plc | 13G | 7.3% | 17.9M | Filed 16 NOV 2026 |
| 16 | CAPR Capricor Therapeutics, Inc. | 13G | 6.6% | 3.4M | Filed 26 JAN 2026 |
| 17 | AVIR Atea Pharmaceuticals, Inc. | 13G | 6.0% | 4.8M | Filed 06 OCT 2026 |
| 18 | SKYE Skye Bioscience, Inc. | 13G | 6.0% | 264K | Filed 14 OCT 2026 |
| 19 | ARDX Ardelyx, Inc. | 13G | 5.7% | 14.3M | Filed 17 NOV 2026 |
| 20 | IMCR Immunocore Holdings plc | 13G | 5.2% | 2.6M | Filed 24 OCT 2025 |
| 21 | KNSA Kiniksa Pharmaceuticals International, plc | 13G | 5.2% | 2.2M | Filed 04 APR 2025 |
| 22 | CBIO Crescent Biopharma, Inc. | 13G | 5.0% | 700K | Filed 09 OCT 2025 |
Showing all 22 disclosed stakes. 8 last disclosed over a year ago (the holder may since have dropped below 5%).
Reading Tang Capital Management LLC’s 13F portfolio
Tang Capital Management LLC’s $2.2B 13F book is spread across 41 reported positions and is highly concentrated — its ten largest positions alone are 63% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are AUPH, SYRE, MIRM, KNSA and CELC, led by AURINIA PHARMACEUTICALS INC (AUPH) at 10% of the portfolio. The heaviest sector exposure is Healthcare (95%), then Technology (1%).
What Tang Capital Management LLC changed last quarter
Between 2026-03-31 and Q2 2026, Tang Capital Management LLC was a net seller: it opened 5 new positions and added to 7 more, while trimming 5 and closing 15 outright. Against a 41-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was AURINIA PHARMACEUTICALS INC (AUPH), and its biggest reduction was STATE STR SPDR S&P 500 ETF T (SPY).
What a 13F does and doesn’t reveal
A 13F captures only Tang Capital Management LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Tang Capital Management LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Tang Capital Management LLC's profile on this page is built directly from those filings.
How current is the 13F data on Tang Capital Management LLC's page?
It reflects Tang Capital Management LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Tang Capital Management LLC files its next quarterly report, this page refreshes automatically.
Can I see Tang Capital Management LLC's complete list of holdings?
This page highlights Tang Capital Management LLC's largest positions rather than all 41 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Tang Capital Management LLC's filings.
Does a 13F show everything Tang Capital Management LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Tang Capital Management LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Tang Capital Management LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

